EULAR 2017 Lilly's Taltz ixekizumab Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks

INDIANAPOLIS June 16 2017 PRNewswire Eli Lilly and Company NYSE LLY announced today that the majority of patients with active psoriatic arthritis PsA treated with Taltz ixekizumab exhibited either no progression or minimal progression of radiographic...